Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin^® in Children and Adults.

ABSTRACT:

Background and objective

Once-daily injectable recombinant human growth hormone (GH) formulations (e.g. Norditropin^®; Novo Nordisk A/S) are used to treat GH deficiency in children and adults, with much of the therapeutic effect mediated via the insulin-like growth factor-I (IGF-I) response. Despite a long history of use, there are few data on the pharmacokinetics and pharmacodynamics (serum IGF-I response) of this therapy, or of potential differences in the relationship of GH pharmacokinetic/pharmacodynamic (PK/PD) effects between children and adults. This study aimed to characterise the GH pharmacokinetics and IGF-I profile following daily subcutaneous GH in adults and children with GH deficiency.

Methods

A model was developed based on a population PK/PD modellin

SUBMITTER: Papathanasiou T 

PROVIDER: S-EPMC8416863 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature